Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Recurrent GBM Brain Tumour Tissue Collection and Cell Extraction
2.3. Primary GBM Cell Culture
2.4. Cytotoxicity of IRN and SN-38 against Patient-Derived GBM Cells
2.5. Clinical Trial: Intraparenchymal Administration of DEBIRI in Recurrent GBM Patients
2.6. Statistical Analysis
3. Results
3.1. Comparison of the Cytotoxicity of IRN and SN-38 Using Primary Cells from Recurrent GBM Patients
3.2. Steroid Use and Swelling in Recurrent GBM Patients after Intraparenchymal Administration of IRN Directly into the Resection Margin Compared to Patients Administered the Gliadel Wafer
3.3. IRN and SN-38 Plasma Concentration after Intraparenchymal Administration of IRN Directly into the Resection Margin
3.4. The Impact of Intraparenchymal Administration of IRN Directly into the Resection Margin on the Survival of Recurrent GBM Patients
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Dolecek, T.A.; Propp, J.M.; Stroup, N.E.; Kruchko, C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012, 14 (Suppl. 5), v1–v49. [Google Scholar] [CrossRef]
- Aldape, K.; Brindle, K.M.; Chesler, L.; Chopra, R.; Gajjar, A.; Gilbert, M.R.; Gottardo, N.; Gutmann, D.H.; Hargrave, D.; Holland, E.C.; et al. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 2019, 16, 509–520. [Google Scholar] [CrossRef]
- Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820. [Google Scholar] [CrossRef]
- Ostrom, Q.T.; Gittleman, H.; Farah, P.; Ondracek, A.; Chen, Y.; Wolinsky, Y.; Stroup, N.E.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013, 15, ii1–ii56. [Google Scholar] [CrossRef]
- Thakkar, J.P.; Dolecek, T.A.; Horbinski, C.; Ostrom, Q.T.; Lightner, D.D.; Barnholtz-Sloan, J.S.; Villano, J.L. Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiol. Biomark. Prev. 2014, 23, 1985–1996. [Google Scholar] [CrossRef] [PubMed]
- Ostrom, Q.T.; Bauchet, L.; Davis, F.; Deltour, I.; Fisher, J.; Langer, C.; Pekmezci, M.; Schwartzbaum, J.A.; Turner, M.C.; Walsh, K.M.; et al. The epidemiology of glioma in adults: A “state of the science” review. Neuro Oncol. 2014, 16, 896–913. [Google Scholar] [CrossRef] [PubMed]
- Dejaegher, J. Recurring Glioblastoma: A Case for Reoperation? In Glioblastoma; De Vleeschouwer, S., Ed.; Codon Publications: Brisbane, Australia, 2017; Volume 27, pp. 281–296. [Google Scholar]
- Robin, A.M.; Lee, I.; Kalkanis, S.N. Reoperation for Recurrent Glioblastoma Multiforme. Neurosurg. Clin. N. Am. 2017, 28, 407–428. [Google Scholar] [CrossRef] [PubMed]
- Reese, T.S.; Karnovsky, M.J. Fine structural localization of a blood–brain barrier to exogenous peroxidase. J. Cell Biol. 1967, 34, 207–217. [Google Scholar] [CrossRef]
- Abbott, N.J.; Romero, I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 1996, 2, 106–113. [Google Scholar] [CrossRef]
- Wang, P.P.; Frazier, J.; Brem, H. Local drug delivery to the brain. Adv. Drug Deliv. Rev. 2002, 54, 987–1013. [Google Scholar] [CrossRef]
- Wolinsky, J.B.; Colson, Y.L.; Grinstaff, M.W. Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers. J. Control. Release 2012, 159, 14–26. [Google Scholar] [CrossRef]
- Qian, F.; Szymanski, A.; Gao, J. Fabrication and characterization of controlled release poly (D,L-lactide-co-glycolide) millirods. J. Biomed. Mater. Res. 2001, 55, 512–522. [Google Scholar] [CrossRef] [PubMed]
- Weinberg, B.D.; Blanco, E.; Gao, J. Polymer Implants for Intratumoral Drug Delivery and Cancer Therapy. J. Pharm. Sci. 2008, 97, 1681–1702. [Google Scholar] [CrossRef]
- McConville, C.; Tawari, P.; Wang, W. Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection. Int. J. Pharm. 2015, 494, 73–82. [Google Scholar] [CrossRef] [PubMed]
- Gawley, M.; Almond, L.; Daniel, S.; Lastakchi, S.; Kaur, S.; Detta, A.; Cruickshank, G.; Miller, R.; Hingtgen, S.; Sheets, K.; et al. Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme. J. Control. Release 2020, 324, 1–16. [Google Scholar] [CrossRef] [PubMed]
- Abdelnabi, D.; Lastakchi, S.; Watts, C.; Atkins, H.; Hingtgen, S.; Valdivia, A.; McConville, C. Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model. Drug Deliv. Transl. Res. 2024, 1–19. [Google Scholar] [CrossRef]
- Krupka, T.M.; Weinberg, B.D.; Ziats, N.P.; Haaga, J.R.; Exner, A.A. Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat. Investig. Radiol. 2006, 41, 890–897. [Google Scholar] [CrossRef]
- Jackson, J.K.; Gleave, M.E.; Yago, V.; Beraldi, E.; Hunter, W.L.; Burt, H.M. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res. 2000, 60, 4146–4151. [Google Scholar]
- Vogl, T.J.; Engelmann, K.; Mack, M.G.; Straub, R.; Zangos, S.; Eichler, K.; Hochmuth, K.; Orenberg, E. CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours. Br. J. Cancer 2002, 86, 524–529. [Google Scholar] [CrossRef]
- Vukelja, S.J.; Anthony, S.P.; Arseneau, J.C.; Berman, B.S.; Cunningham, C.C.; Nemunaitis, J.J.; Samlowski, W.E.; Fowers, K.D. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anti-Cancer Drugs 2007, 18, 283–289. [Google Scholar] [CrossRef]
- Menei, P.; Capelle, L.; Guyotat, J.; Fuentes, S.; Assaker, R.; Bataille, B.; François, P.; Dorwling-Carter, D.; Paquis, P.; Bauchet, L.; et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: A randomized phase II trial. Neurosurgery 2005, 56, 242–248. [Google Scholar] [CrossRef] [PubMed]
- Beduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28, 4947–4967. [Google Scholar] [CrossRef]
- Meyers, J.D.; Doane, T.; Burda, C.; Basilion, J.P. Nanoparticles for imaging and treating brain cancer. Nanomedicine 2013, 8, 123–143. [Google Scholar] [CrossRef] [PubMed]
- Fleming, A.B.; Saltzman, W.M. Pharmacokinetics of the carmustine implant. Clin. Pharm. 2002, 41, 403–419. [Google Scholar] [CrossRef] [PubMed]
- Valtonen, S.; Timonen, U.; Toivanen, P.; Kalimo, H.; Kivipelto, L.; Heiskanen, O.; Unsgaard, G.; Kuurne, T. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 1997, 41, 44–48. [Google Scholar] [CrossRef] [PubMed]
- Westphal, M.; Hilt, D.C.; Bortey, E.; Delavault, P.; Olivares, R.; Warnke, P.C.; Whittle, I.R.; Jääskeläinen, J.; Ram, Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003, 5, 79–88. [Google Scholar] [CrossRef]
- Brem, H.; Piantadosi, S.; Burger, P.C. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrence. Lancet 1995, 345, 1008–1012. [Google Scholar] [CrossRef]
- Hart, M.G.; Grant, R.; Garside, R.; Rogers, G.; Somerville, M.; Stein, K.; Grant, R. Chemotherapeutic wafers for High Grade Glioma. Cochrane Database Syst. Rev. 2011, 16, CD007294. [Google Scholar]
- Brem, H.; Gabikian, P. Biodegradable polymer implants to treat brain tumors. J. Control. Release 2001, 74, 63–67. [Google Scholar] [CrossRef]
- Weber, E.L.; Goebel, E.A. Cerebral edema associated with Gliadel wafers: Two case studies. Neuro Oncol. 2005, 7, 84–89. [Google Scholar] [CrossRef]
- Chowdhary, S.A.; Ryken, T.; Newton, H.B. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: A meta-analysis. J. Neuro Oncol. 2015, 122, 367–382. [Google Scholar] [CrossRef] [PubMed]
- Ramesh, M.; Ahlawat, P.; Srinivas, N. Irinotecan and its active metabolite, SN-38: Review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed. Chromatogr. 2010, 24, 104–123. [Google Scholar] [CrossRef]
- Xu, Y. Irinotecan: Mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 2002, 13, 1841–1851. [Google Scholar] [CrossRef] [PubMed]
- Sinha, B. Topoisomerase Inhibitors. Drugs 1995, 49, 11–19. [Google Scholar] [CrossRef] [PubMed]
- Vrendenburgh, J.; Desjardins, A.; Reardon, D.A.; Friedman, H.S. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009, 11, 80–91. [Google Scholar] [CrossRef]
- Saunders, M.; Iveson, T. Management of advanced colorectal cancer: State of the art. Br. J. Cancer 2006, 95, 131–138. [Google Scholar] [CrossRef]
- Friedman, H.S.; Petros, W.P.; Friedman, A.H.; Schaaf, L.J.; Kerby, T.; Lawyer, J.; Parry, M.; Houghton, P.J.; Lovell, S.; Rasheed, K.; et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 1999, 17, 1516–1525. [Google Scholar] [CrossRef]
- Buckner, J.C.; Reid, J.M.; Wright, K.; Kaufmann, S.H.; Erlichman, C.; Ames, M.; Cha, S.; O’Fallon, J.R.; Schaaf, L.J.; Miller, L.L. Irinotecan in the treatment of glioma patients: Current and future studies of the North Central Cancer Treatment Group. Cancer 2003, 97, 2352–2358. [Google Scholar] [CrossRef]
- Raymond, E.; Fabbro, M.; Boige, V.; Rixe, O.; Frenay, M.; Vassal, G.; Faivre, S.; Sicard, E.; Germa, C.; Rodier, J.M.; et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol. 2003, 14, 603–614. [Google Scholar] [CrossRef]
- Chamberlain, M.C. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Neuro Oncol. 2002, 56, 183–188. [Google Scholar] [CrossRef]
- Turner, C.D.; Gururangan, S.; Eastwood, J.; Bottom, K.; Watral, M.; Beason, R.; McLendon, R.E.; Friedman, A.H.; Tourt-Uhlig, S.; Miller, L.L.; et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience. Neuro Oncol. 2004, 4, 102–108. [Google Scholar] [CrossRef]
- Cloughesy, T.F.; Filka, E.; Nelson, G.; Kabbinavar, G.F.; Friedman, H.; Miller, L.L.; Elfring, G.L. Irinotecan treatment for recurrent malignant glioma using an every-three-week regimen. Am. J. Clin. Oncol. 2002, 25, 204–208. [Google Scholar] [CrossRef] [PubMed]
- Batchelor, T.T.; Gilbert, M.R.; Supko, J.G.; Carson, K.A.; Nabors, L.B.; Grossman, S.A.; Lesser, G.L.; Mikkelsen, T.; Phuphanich, P. NABTT CNS Consortium, Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97–11. Neuro Oncol. 2004, 6, 21–27. [Google Scholar] [CrossRef]
- Gilbert, M.R.; Supko, J.G.; Batchelor, T.; Lesser, G.; Fisher, J.D.; Piantadosi, S.; Grossman, S. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. 2003, 9, 2940–2949. [Google Scholar] [PubMed]
- Prados, M.D.; Lamborn, K.; Yung, W.K.A.; Jaeckle, K.A.; Robins, H.I.; Mehta, M.P.; Fine, H.A.; Wen, P.Y.; Cloughesy, T.; Chang, S.; et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro Oncol. 2006, 8, 189–193. [Google Scholar] [CrossRef] [PubMed]
- Yung, W.K.A.; Lieberman, F.S.; Wen, P.; Robin, I.; Gilbert, M.; Chang, S.; Junck, L.; Cloughesy, T.; Lamborn, K.; Prados, M. Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study. J. Clin. Oncol. 2005, 23, 1521. [Google Scholar] [CrossRef]
- Gruber, M.L.; Buster, W.P. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am. J. Clin. Oncol. 2004, 27, 33–38. [Google Scholar] [CrossRef]
- Brandes, A.A.; Tosoni, A.; Basso, U.; Reni, M.; Valduga, F.; Monfardini, S.; Amistà, P.; Nicolardi, L.; Sotti, G.; Ermani, M. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol. 2004, 22, 4779–4786. [Google Scholar] [CrossRef]
- Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Gururangan, S.; Vredenburgh, J.; Sampson, J.H.; Provenzale, J.M.; Walker, A.; Badruddoja, M.; Tourt-Uhlig, S.; et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004, 6, 134–144. [Google Scholar] [CrossRef]
- Quinn, J.A.; Reardon, D.A.; Friedman, A.H.; Rich, J.N.; Sampson, J.H.; Vredenburgh, J.; Gururangan, S.; Provenzale, J.M.; Walker, A.; Schweitzer, H.; et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004, 6, 145–153. [Google Scholar] [CrossRef]
- Purow, B.; Fine, H.A. Antiangiogenic therapy for primary and metastatic brain tumors. Hematol. Oncol. Clin. N. Am. 2004, 18, 1161–1181. [Google Scholar] [CrossRef]
- Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E.; Dowell, J.M.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Clin. Cancer Res. 2007, 13, 1253–1259. [Google Scholar] [CrossRef]
- Goli, K.J.; Desjardins, A.; Herndon, J.E.; Rich, J.N.; Reardon, D.A.; Quinn, J.A.; Sathornsumetee, S.; Bota, D.A.; Friedman, H.S.; Vredenburgh, J.J. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. J. Clin. Oncol. 2007, 25, 2003. [Google Scholar] [CrossRef]
- Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E.; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25, 4722–4729. [Google Scholar] [CrossRef] [PubMed]
- Raval, S.; Hwang, S.; Dorsett, L. Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. 2007, 25, 2078. [Google Scholar] [CrossRef]
- Bokstein, F.; Shpigel, S.; Blumenthal, D.T. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008, 15, 2267–2273. [Google Scholar] [CrossRef]
- Friedman, H.S.; Prados, M.D.; Wen, P.Y.; Mikkelsen, T.; Schiff, D.; Abrey, L.E.; Yung, W.K.A.; Paleologos, N.; Nicholas, M.K.; Jensen, R.; et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 1, 4733–4740. [Google Scholar] [CrossRef]
- Mesti, T.; Moltara, M.E.; Boc, M.; Rebersek, M.; Ocvirk, J. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol. Oncol. 2015, 49, 80–85. [Google Scholar] [CrossRef]
- Ozel, O.; Kurt, M.; Ozdemir, O.; Bayram, J.; Akdeniz, H.; Koca, D. Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review. J. Oncol. Sci. 2016, 2, 87–94. [Google Scholar] [CrossRef]
- Hecht, J.R. Gastrointestinal Toxicity of Irinotecan. Oncology 1998, 12, 73–78. [Google Scholar]
- Baltes, S.; Freund, I.; Lewis, A.; Nolte, I.; Brinker, T. Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: A pilot study in a rat model. J. Mater. Sci. 2010, 21, 1393–1402. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Ghandi, A.; Liebes, L.; Louie, S.G.; Hofman, F.M.; Schönthal, A.H.; Chen, T.C. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. J. Neurosurg. 2011, 114, 689–694. [Google Scholar] [CrossRef] [PubMed]
- Humerickhouse, R.; Lohrbach, K.; Li, L.; Bosron, W.F.; Dolan, M.E. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 2000, 60, 1189–1192. [Google Scholar]
- Brem, H.; Mahaley Jr, M.S.; Vick, N.A.; Black, K.L.; Schold, S.C.; Burger, P.C.; Friedman, A.H.; Ciric, I.S.; Eller, T.W.; Cozzens, J.W.; et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 1991, 74, 441–446. [Google Scholar] [CrossRef] [PubMed]
- Pitter, K.L.; Tamagno, I.; Alikhanyan, K.; Hosni-Ahmed, A.; Pattwell, S.S.; Donnola, S.; Dai, C.; Ozawa, T.; Chang, M.; Chan, T.A.; et al. Corticosteroids compromise survival in glioblastoma. Brain 2016, 139, 1458–1471. [Google Scholar] [CrossRef] [PubMed]
- Whittle, I.R.; Ashkan, K.; Grundy, P.; Cruickshank, G. NICE guidance on the use of carmustine wafers in high grade gliomas: A national study on variation in practice. Br. J. Neurosurg. 2012, 26, 331–335. [Google Scholar]
- Gupta, E.; Lestingi, T.M.; Mick, R.; Ramirez, J.; Vokes, E.E.; Ratain, M.J. Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea. Cancer Res. 1994, 54, 3723–3725. [Google Scholar]
Patient | Age | Sex | Karnofsky Score | Prior Surgery | Prior Chemotherapy | IDH | MGMT Status | AED | Dexamethasone |
---|---|---|---|---|---|---|---|---|---|
1 | 51 | M | 100 | ×2 | 2× TMZ, 1× PCV | Mutant | Unmethylated | Lev | No |
2 | 29 | M | 100 | ×1 | 1× TMZ, 1× PCV | Mutant | Methylated | Lev | Yes |
3 | 56 | M | 90 | ×2 | 1× TMZ | Wild type | Methylated | Lev | No |
4 | 73 | M | 80 | ×1 | 1× PCV | Wild type | Unmethylated | Lev | Yes |
5 | 60 | F | 100 | ×1 | 1× PCV | Wild type | Methylated | Lev | Yes |
6 | 63 | M | 80 | ×1 | 1× TMZ, 1× PCV | Wild type | Unmethylated | none | Yes |
7 | 44 | M | 90 | ×2 | 1× TMZ | Mutant | Methylated | none | No |
8 | 53 | M | 80 | ×2 | 1× PCV | Wild type | Methylated | Lev | Yes |
9 | 63 | M | 90 | ×1 | 1× TMZ, 1× PCV | Wild type | Unmethylated | Lev | Yes |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
McConville, C.; Lastakchi, S.; Al Amri, A.; Ngoga, D.; Fayeye, O.; Cruickshank, G. Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration. Cancers 2024, 16, 3008. https://doi.org/10.3390/cancers16173008
McConville C, Lastakchi S, Al Amri A, Ngoga D, Fayeye O, Cruickshank G. Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration. Cancers. 2024; 16(17):3008. https://doi.org/10.3390/cancers16173008
Chicago/Turabian StyleMcConville, Christopher, Sarah Lastakchi, Ali Al Amri, Desire Ngoga, Oluwafikayo Fayeye, and Garth Cruickshank. 2024. "Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration" Cancers 16, no. 17: 3008. https://doi.org/10.3390/cancers16173008